No Data
No Data
Kehua Biotech (002022.SZ): 2 products obtained medical device registration certificates
Gelonghui, April 12, 丨 Kehua Biotech (002022.SZ) announced that recently, Shanghai Kehua Bioengineering Co., Ltd. received the “Medical Device Registration Certificate” (in vitro diagnostic reagent) issued by the State Drug Administration. They are hepatitis E virus IgM antibody test kit (chemiluminescence method) and hepatitis B virus core IgM antibody test kit (chemiluminescence method), respectively.
Kehua Biotech (002022.SZ): The company has no hemorrhoid and laxative testing related products
Gelonghui, April 3 | Kehua Biotech (002022.SZ) said on the investor interactive platform that the company has no products related to hemorrhoid and laxative testing.
Kehua Biotech (002022.SZ): 1.67% of shares have been repurchased cumulatively
Gelonghui, April 1, 丨 Kehua Biotech (002022.SZ) announced that as of March 31, 2024, the total number of shares repurchased by the company through centralized bidding transactions was 8,575,800 shares, accounting for 1.67% of the company's current total share capital. The highest transaction price was 10.68 yuan/share, the minimum transaction price was 6.37 yuan/share, and the transaction amount was 69,765,653.16 yuan (excluding transaction fees).
Kehua Biotech (002022.SZ): 2023 net loss of 234 million yuan
Gelonghui, March 22丨Kehua Biotech (002022.SZ) released its 2023 annual report. In 2023, the company achieved operating income of 2,428 billion yuan, a year-on-year decrease of 65.16%; net profit attributable to shareholders of listed companies was -234 million yuan, year-on-year profit and loss; net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was -280 million yuan; basic earnings per share was -0.4550 yuan
Kehua Biology (002022.SZ): Has products related to HIV testing
Gelonghui March 22丨An investor asked Kehua Biotech (002022.SZ) on the investor interactive platform, “Does your company have a layout in the field of anti-AIDS drugs?” The company replied that its main business is R&D, production and sales of in vitro diagnostic reagents and medical testing instruments, and that the company has products related to HIV testing.
Kehua Biotech (002022.SZ): The UPLC Xevo TQ-S tandem mass spectrometry system is the company's agent
Gelonghui March 19 | Kehua Biotech (002022.SZ) said on the investor interactive platform that the UPLC Xevo TQ-S tandem mass spectrometry system is a product represented by the company.
No Data